Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
Lexeo Therapeutics, a US-based gene therapy developer founded out of Weill Cornell Medicine, has emerged from stealth with an oversubscribed $85m series A round co-led by healthcare-focused venture capital firm Longitude Capital and investment firm Omega Funds.
Pharmaceutical firm Lundbeck and life sciences real estate investment firm Alexandria Real Estate Equities participated through their subsidiaries Lundbeckfonden Ventures and Alexandria Venture Investments.
The transcation also attracted nonprofit research organisation Alzheimer’s Drug Discovery Foundation, PBM Capital, Janus Henderson Investors, Invus…